RxDoctor Payments Data

Chante Ellison-Hodges, MD

Family Medicine · Tomball, TXNPI 1548338619

Payments from drug & device makers

$2,840in general payments, 2019–2025

Across 141 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$611
  • Lilly USA, LLC$420
  • Amgen$385
  • AstraZeneca$188
  • AbbVie$180
  • Abbott$124
  • plus $932 from 21 others

What the payments were for

  • Food & beverage$2,826100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,840 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$43,284
Medicare patients
124
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$68,119
OzempicSemaglutide36$51,585
TrulicityDulaglutide31$50,151
FarxigaDapagliflozin Propanediol21$29,238
RybelsusSemaglutide22$26,128
JardianceEmpagliflozin15$19,027
JanuviaSitagliptin Phosphate13$18,291
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,185
VascepaIcosapent Ethyl19$11,814
Rosuvastatin Calcium197$3,946
Atorvastatin Calcium180$2,452
Nifedipine ErNifedipine55$1,661
Gabapentin107$1,563
Levothyroxine Sodium190$1,561
Pantoprazole Sodium114$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$420$118,27073 claims
Novo NordiskOzempic, Rybelsus$611$77,71358 claims
AstraZenecaFarxiga$188$29,23821 claims
Boehringer IngelheimJardiance$34$19,02715 claims
MerckJanuvia$31$18,29113 claims
GSKTrelegy Ellipta$111$14,18517 claims
AbbVieSynthroid$180$1,26612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →